Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SLS vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLS Captures Overall Composite Edge (34.1 SELL vs 43.9 HOLD), While CAMP Leads 3–2 on Growth & Valuation Pillars

SLS Overall Winner 6-Pillar Tally: SLS 2 – 3 CAMP (1 Tie) Matrix Metrics: SLS 4 – 3 CAMP

As of Nov 17, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (34.1/100 SELL vs. 43.9/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. SLS trades at $19.15 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin).

  • Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. SLS 34.1/100 SELL), SLS captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -991.8% operating margin) and revenue trajectory (-82.5% vs. +138.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLS vs CAMP
SLS NASDAQ Head-to-Head Winner
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$19.15
+156.36% 1D
Market Cap $1.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.38β · 568% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 5.0 Fund 37.0 Flow 66.0 Mom 38.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 77
RSI-14: 77.3 · SMA20: $10.00 · SMA50: $11.02
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$4.00
+3.63% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.35β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (SLS 2 – 3 CAMP)

Columns: Metric · SLS · CAMP
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 26.6x
2. Growth & Scale CAMP
Revenue Growth (YoY) -82.5% +138.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $5.3M
Market Cap $1.6B $238.5M
3. Profitability & Quality SLS
Gross Margin N/A N/A
Operating Margin 0.0% -991.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -40.3% -146.1%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$28M -$26M
Cash Flow Margin N/A N/A
Net Cash / Leverage $138M Net Cash $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLS
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 545.8% (74th %ile) N/A (N/A)
Put/Call OI Skew 0.39x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLS (4) vs CAMP (3)
Institutional Metric SLS CAMP Criterion Row Edge
Market Capitalization
Scale
$1.6B $238.5M Larger Scale SLS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-82.5% +138.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
0.0% -991.8% Higher Margin SLS
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-40.3% -146.1% Higher ROE SLS
52-Week Range Position
Momentum
76% ($1–$25) 23% ($3–$8) Stronger Trend SLS
Beta / 30D Volatility
Risk Regime
1.38β · 568% Vol 1.35β · 94% Vol Lower Realized Risk CAMP
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 43.9 / 100 (HOLD) Higher Composite CAMP
Trailing 12M Revenue (USD)
Operating Scale
N/A $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($138M Net Cash) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLS +55.16 pp
SLS: +82.55% · CAMP: +27.39%
3M Horizon SLS +52.25 pp
SLS: +38.27% · CAMP: -13.98%
6M Horizon SLS +155.92 pp
SLS: +152.31% · CAMP: -3.61%
1Y Horizon SLS +1241.6 pp
SLS: +1239.16% · CAMP: -2.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SLS Revenue CAMP Revenue SLS Op. Margin CAMP Op. Margin Margin Leader
FY2013 $0M N/A -1145.5% N/A SLS
FY2014 $10M N/A -471.1% N/A SLS
FY2020 $0M N/A -893.8% N/A SLS
FY2021 $10M N/A -332.8% N/A SLS
FY2022 $0M N/A -4195.0% N/A SLS
FY2023 N/A $0M N/A -14822.6% CAMP
FY2024 N/A $0M N/A -8142.3% CAMP
FY2025 N/A $0M N/A -1502.4% CAMP

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLS BREAKOUT
99d in phase · OBV ACCUMULATION
Current IV 545.8%
IV Percentile 74th %ile
Put/Call OI Skew 0.39x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact SLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SLS vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (34.1/100 SELL vs. 43.9/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. SLS trades at $19.15 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin). Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. SLS 34.1/100 SELL), SLS captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -991.8% operating margin) and revenue trajectory (-82.5% vs. +138.9% YoY).

CAMP leads the Growth & Scale pillar: SLS posts -82.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), SLS cumulative revenue shifted +0.0% while CAMP shifted N/A. In operating R&D and SG&A reinvestment, SLS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

CAMP screens cheaper on headline valuation multiples. SLS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLS (-40.3% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SLS carries 545.8% implied volatility (74th %ile, Elevated (60th–80th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.38β · 568% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.